iC Biosolutions produces acellular secretome therapeutics derived from GMP‑compliant iPSC banks, delivering the regenerative and anti‑inflammatory signaling of stem cells without live cells. The platform offers a scalable, donor‑independent biologic with consistent paracrine activity for veterinary joint disease treatment, and a pipeline adaptable to other animal species and human indications.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for chronic inflammatory and degenerative diseases often rely on live-cell therapies, which present challenges such as high manufacturing complexity, batch‑to‑batch variability, safety risks from viable cells, and limited scalability. These issues restrict broader clinical use and increase costs, especially for veterinary and human applications.
Solution
iC Biosolutions creates acellular secretome therapeutics that capture the regenerative and anti‑inflammatory signaling of stem cells without using live cells. The platform leverages GMP‑compliant induced pluripotent stem cell banks and directed differentiation to produce a donor‑independent secretome in a controlled, scalable manufacturing process. The resulting biologic retains paracrine activity that modulates core inflammatory and tissue‑repair pathways while offering a safer, more consistent product profile. Clinical translation is supported by rigorous in‑vitro and ex‑vivo validation, a reproducible quality system, and a stepwise development strategy that begins with equine joint disease and expands to companion animals and eventually human indications.
Target Audience
Primary customers are veterinary pharmaceutical companies and large animal health practices seeking disease‑modifying treatments for chronic joint and inflammatory conditions, with future focus on human biotech partners developing regenerative biologics.
Features
- GMP‑compliant iPSC banks provide a renewable, standardized source for secretome production
- Directed differentiation and acellular manufacturing yield donor‑independent biologics with reduced variability
- Controlled paracrine signaling modulates inflammatory and regenerative pathways
- Scalable production pipeline designed for reproducibility and regulatory alignment
- Preclinical and clinical validation in equine joint disease (ICB001) demonstrating safety and efficacy
- Platform architecture enables rapid adaptation to additional species (dogs, cats) and human therapeutic targets